Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma, Clear Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 11Fluorouracil 8Cisplatin 6Oxaliplatin 5Carboplatin 5Paclitaxel 4Neoadjuvant Therapy 4Leucovorin 4Gefitinib 4pembrolizumab 3Radiation 3Irinotecan 3Taxes 2Surgical Procedures, Operative 2Gemcitabine 2Docetaxel 2Cetuximab 2130-nm albumin-bound paclitaxel 2vandetanib 1spartalizumab 1sargramostim 1romidepsin 1ribociclib 1regorafenib 1oblimersen 1incomplete Freund's adjuvant 1fish oil triglycerides 1dehydroftorafur 1ceritinib 1benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma Of Esophagus × AMG 337 × Clear all
NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Amgen

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡